


## (S)-Ceralasertib

Cat. No.:	HY-19323A		
CAS No.:	1352226-87-9		
Molecular Formula:	C <sub>20</sub> H <sub>24</sub> N <sub>6</sub> O <sub>2</sub> S		
Molecular Weight:	412.51		
Target:	ATM/ATR		
Pathway:	Cell Cycle/DNA Damage; PI3K/Akt/mTOR		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

#### Description

(S)-Ceralasertib is extracted from patent WO2011154737A1, Compound II, exhibits an IC<sub>50</sub> of 2.578 nM<sup>[1]</sup>. (S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical and pharmacokinetic (PK) characteristics. (S)-Ceralasertib is developed improving aqueous solubility and eliminates CYP3A4 time-dependent inhibition<sup>[2]</sup>.

### REFERENCES

- [1]. By Foote, et al. Morpholinopyrimidines as ATR kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. PCT Int. Appl. (2011), WO 2011154737 A1 20111215.
- [2]. Foote KM, et al. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. J Med Chem. 2018 Nov 21;61(22):9889-9907.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA